During the last session, AbCellera Biologics Inc (NASDAQ:ABCL)’s traded shares were 1.23 million, with the beta value of the company hitting 0.37. At the end of the trading day, the stock’s price was $2.78, reflecting an intraday loss of -1.77% or -$0.05. The 52-week high for the ABCL share is $6.05, that puts it down -117.63 from that peak though still a striking 15.83% gain since the share price plummeted to a 52-week low of $2.34. The company’s market capitalization is $819.17M, and the average intraday trading volume over the past 10 days was 2.07 million shares, and the average trade volume was 1.90 million shares over the past three months.
AbCellera Biologics Inc (ABCL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.22. ABCL has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.15.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
The stock plummet -1.77% in intraday trading to $2.78, hitting a weekly high. The stock’s 5-day price performance is 0.00%, and it has moved by 8.17% in 30 days. Based on these gigs, the overall price performance for the year is -31.19%. The short interest in AbCellera Biologics Inc (NASDAQ:ABCL) is 17.35 million shares and it means that shorts have 10.12 day(s) to cover.
The consensus price target of analysts on Wall Street is $29, which implies an increase of 90.41% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $34 respectively. As a result, ABCL is trading at a discount of -1123.02% off the target high and -79.86% off the low.
AbCellera Biologics Inc (ABCL) estimates and forecasts
Statistics show that AbCellera Biologics Inc has underperformed its competitors in share price, compared to the industry in which it operates. AbCellera Biologics Inc (ABCL) shares have gone down -26.46% during the last six months, with a year-to-date growth rate less than the industry average at -7.84% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -50.00% this quarter and then jump 5.90% in the quarter after that. In the rating firms’ projections, revenue will decrease -11.60% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 7.95M as predicted by 9 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 8.24M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 11.84M and 9.18M respectively. In this case, analysts expect current quarter sales to shrink by -32.90% and then drop by -10.20% in the coming quarter.
While earnings are projected to return 10.68% in 2024, the next five years will return 10.00% per annum.
ABCL Dividends
AbCellera Biologics Inc is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
AbCellera Biologics Inc insiders own 28.05% of total outstanding shares while institutional holders control 38.36%, with the float percentage being 53.32%. BAKER BROS. ADVISORS LP is the largest shareholder of the company, while 214.0 institutions own stock in it. As of 2024-06-30, the company held over 27.53 million shares (or 9.4033% of all shares), a total value of $81.48 million in shares.
The next largest institutional holding, with 21.91 million shares, is of BAILLIE GIFFORD & CO’s that is approximately 7.4852% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.86 million.
